Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | FOG-001 |
| Trade Name | |
| Synonyms | FOG 001|FOG001 |
| Drug Descriptions |
FOG-001 inhibits the interaction between beta-catenin (CTNNB1) and TCF, resulting in decreased Wnt pathway signaling and potentially leading to decreased tumor growth (J Clin Oncol 42, 2024 (suppl 16; TPS3175), NCI Drug Dictionary) |
| DrugClasses | CTNNB1 Inhibitor 27 |
| CAS Registry Number | NA |
| NCIT ID | C201235 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Bevacizumab + Fluorouracil + FOG-001 + Leucovorin + Oxaliplatin | Bevacizumab FOG-001 Fluorouracil Leucovorin Oxaliplatin | 0 | 1 |
| Bevacizumab + FOG-001 + Trifluridine-tipiracil hydrochloride | Bevacizumab FOG-001 Trifluridine-tipiracil hydrochloride | 0 | 1 |
| FOG-001 | FOG-001 | 0 | 1 |
| FOG-001 + Nivolumab | FOG-001 Nivolumab | 0 | 1 |